IL319254A - תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג - Google Patents
תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוגInfo
- Publication number
- IL319254A IL319254A IL319254A IL31925425A IL319254A IL 319254 A IL319254 A IL 319254A IL 319254 A IL319254 A IL 319254A IL 31925425 A IL31925425 A IL 31925425A IL 319254 A IL319254 A IL 319254A
- Authority
- IL
- Israel
- Prior art keywords
- kat2
- pyridazinon
- degraders
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263403401P | 2022-09-02 | 2022-09-02 | |
| US202363460764P | 2023-04-20 | 2023-04-20 | |
| PCT/US2023/031835 WO2024050078A1 (en) | 2022-09-02 | 2023-09-01 | Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319254A true IL319254A (he) | 2025-04-01 |
Family
ID=88192267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319254A IL319254A (he) | 2022-09-02 | 2023-09-01 | תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4581025A1 (he) |
| JP (1) | JP2025530801A (he) |
| KR (1) | KR20250077607A (he) |
| CN (1) | CN120112525A (he) |
| AU (1) | AU2023333181A1 (he) |
| CA (1) | CA3266556A1 (he) |
| IL (1) | IL319254A (he) |
| MX (1) | MX2025002519A (he) |
| WO (1) | WO2024050078A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
| CN120794955A (zh) * | 2025-07-07 | 2025-10-17 | 四川伊诺唯新生物医药有限公司 | 一种irak4靶向蛋白降解剂关键中间体的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3189046B1 (en) | 2014-09-05 | 2020-08-26 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3189049B1 (en) | 2014-09-05 | 2024-03-20 | Genentech, Inc. | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer |
| EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
| AU2016349781A1 (en) * | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3947368B1 (en) * | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
-
2023
- 2023-09-01 WO PCT/US2023/031835 patent/WO2024050078A1/en not_active Ceased
- 2023-09-01 EP EP23776776.9A patent/EP4581025A1/en active Pending
- 2023-09-01 JP JP2025513363A patent/JP2025530801A/ja active Pending
- 2023-09-01 KR KR1020257008598A patent/KR20250077607A/ko active Pending
- 2023-09-01 IL IL319254A patent/IL319254A/he unknown
- 2023-09-01 CN CN202380075140.2A patent/CN120112525A/zh active Pending
- 2023-09-01 CA CA3266556A patent/CA3266556A1/en active Pending
- 2023-09-01 AU AU2023333181A patent/AU2023333181A1/en active Pending
-
2025
- 2025-02-28 MX MX2025002519A patent/MX2025002519A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025530801A (ja) | 2025-09-17 |
| CN120112525A (zh) | 2025-06-06 |
| MX2025002519A (es) | 2025-06-02 |
| WO2024050078A1 (en) | 2024-03-07 |
| AU2023333181A1 (en) | 2025-03-13 |
| EP4581025A1 (en) | 2025-07-09 |
| KR20250077607A (ko) | 2025-05-30 |
| CA3266556A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287280A (he) | תרכובות ושיטות לטיפול בהפרעות עיניות | |
| IL319254A (he) | תולדות פירידזינון כמפרקיkat2 לטיפול בהפרעות שגשוג | |
| IL304595A (he) | נגזרות טטרהידרוזפין ביציקליות לטיפול בסרטן | |
| IL287264A (he) | תרכובות ושיטות לטיפול בהפרעות עיניות | |
| GB202020549D0 (en) | Treatment for Lysine Degradation-associated Disorders | |
| IL286756A (he) | ליפוקלין מוטאין לטיפול באסטמה | |
| PL4143179T3 (pl) | Pochodne azetydyn-3-ylometanolu jako modulatory receptora ccr6 do leczenia nowotworu | |
| EP4294388A4 (en) | OXA-IBOGAIN ANALOGUES FOR THE TREATMENT OF SUBSTANCE ABUSE | |
| EP4010347A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS | |
| EP3883567B8 (en) | Naphthyridinone-aniline compounds for treatment of dermal disorders | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| IL289221A (he) | תרכובות לטיפול בהפרעות ראייה | |
| CA3261797A1 (en) | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| IL290540A (he) | תרכובות המתאימות לטיפול ומניעה של דלדול שרירים ומצבים אחרים | |
| IL321845A (he) | נגזרות 1-אמינו-4-פנילפתלזין שימושיות לטיפול במחלות ניוון עצביות | |
| IL290035A (he) | תולדות פירידין כמאפנני tmem16a לשימוש בטיפול במצבים נשימתיים | |
| IL288234A (he) | תרכובות לטיפול בהפרעות עצביות-שריריות | |
| EP4232458A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES | |
| GB202110563D0 (en) | Device for the treatment of foot conditions | |
| EP3777759A4 (en) | Apparatus for treating surface of medical metal | |
| EP4037689A4 (en) | 18-MC ON SUBSTANCE ABUSE TREATMENT | |
| GB202103887D0 (en) | Compounds for the treatment of bone disorders | |
| HK40106221A (en) | Compounds for use in the treatment of hyperproliferative disorders | |
| GB202101161D0 (en) | Formulations for the treatment of tendinopathies | |
| GB202001137D0 (en) | Formulations for the treatment of tendinopathies |